Abstract
Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease. Ongoing clinical trials are in place to address the role of raloxifene and SERMs in each of these areas. We review the pharmacology, clinical utility, safety and tolerability of raloxifene and speculate on what the future holds for SERMs and their use in breast cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 334-340 |
| Number of pages | 7 |
| Journal | Expert review of anticancer therapy |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2001 |
| Externally published | Yes |
Keywords
- Agonist
- Antagonist
- Antiestrogens
- Chemoprevention
- Cross-resistance
- Osteoporosis
- Raloxifene
- Selective estrogen receptor modulation
- Tamoxifen
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)